Globeflex Capital L P Makes New Investment in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Globeflex Capital L P purchased a new stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 125,210 shares of the company's stock, valued at approximately $424,000. Globeflex Capital L P owned approximately 0.08% of Xeris Biopharma as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Geode Capital Management LLC lifted its position in shares of Xeris Biopharma by 2.9% during the 3rd quarter. Geode Capital Management LLC now owns 3,333,470 shares of the company's stock valued at $9,502,000 after acquiring an additional 93,091 shares during the period. Walleye Capital LLC acquired a new position in Xeris Biopharma during the third quarter worth $3,197,000. Essex Investment Management Co. LLC purchased a new stake in Xeris Biopharma during the fourth quarter worth $1,610,000. Wellington Management Group LLP grew its holdings in Xeris Biopharma by 11.7% in the third quarter. Wellington Management Group LLP now owns 471,644 shares of the company's stock valued at $1,344,000 after purchasing an additional 49,535 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its position in shares of Xeris Biopharma by 20.8% in the third quarter. JPMorgan Chase & Co. now owns 391,960 shares of the company's stock valued at $1,117,000 after buying an additional 67,557 shares in the last quarter. Institutional investors and hedge funds own 42.75% of the company's stock.

Xeris Biopharma Trading Down 1.5 %

Shares of Xeris Biopharma stock traded down $0.08 during trading hours on Thursday, reaching $5.43. 3,757,045 shares of the company's stock were exchanged, compared to its average volume of 2,352,072. The firm has a market capitalization of $835.89 million, a price-to-earnings ratio of -12.07 and a beta of 2.32. Xeris Biopharma Holdings, Inc. has a 52-week low of $1.69 and a 52-week high of $5.54. The company has a fifty day moving average of $3.79 and a 200-day moving average of $3.37.

Remove Ads

Wall Street Analyst Weigh In

A number of brokerages recently commented on XERS. Leerink Partners increased their price objective on shares of Xeris Biopharma from $5.00 to $6.00 and gave the company an "outperform" rating in a research note on Friday, March 7th. Craig Hallum raised their price objective on shares of Xeris Biopharma from $5.00 to $6.50 and gave the stock a "buy" rating in a research note on Friday, March 7th. HC Wainwright reaffirmed a "buy" rating and issued a $8.00 target price (up previously from $6.60) on shares of Xeris Biopharma in a research note on Friday, March 7th. Jefferies Financial Group reissued a "buy" rating and set a $6.00 price target (up previously from $4.00) on shares of Xeris Biopharma in a research report on Wednesday, January 29th. Finally, Piper Sandler restated a "neutral" rating and issued a $4.00 price objective (up from $3.00) on shares of Xeris Biopharma in a research report on Friday, March 7th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $5.92.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.